Internal restructuring
Este; Cataluña; Barcelona
Location of affected unit(s)
Manufacture Of Chemicals And Pharamceuticals
Manufacture Of Basic Pharmaceutical Products And Pharmaceutical Preparations
21.10 - Manufacture of basic pharmaceutical products

2,300 jobs
Number of planned job losses
Job loss
Announcement Date
15 February 2023
Employment effect (start)
5 March 2023
Foreseen end date
31 December 2023


Grifols, a Spanish global healthcare company and world leader in essential plasma-derived medicines and transfusion medicine, has announced an operational improvement plan to save 400 million euros a year from 2024, including an 8% reduction in its workforce, i.e. 2300 employees. In this regard, the plan envisages the dismissal of 2000 employees in the plasma business in the United States and another 300 in corporate functions, including approximately 100 redundancies in Spain. The objective of the plan is to increase the company's competitiveness, reduce its cost base and improve organisational agility, efficiency and effectiveness. The company expects most of the measures (including those related to employment) to be implemented by the last quarter of this year.



Eurofound (2023), Grifols, Internal restructuring in Spain, factsheet number 108406, European Restructuring Monitor. Dublin, https://restructuringeventsprod.azurewebsites.net/restructuring-events/detail/108406.